Illumina (NASDAQ:ILMN) was upgraded by equities researchers at Wells Fargo & Co to an “outperform” rating in a note issued to investors on Tuesday, The Fly reports.
Several other equities analysts also recently weighed in on the company. Leerink Swann restated an “outperform” rating and issued a $225.00 target price (up previously from $207.00) on shares of Illumina in a research report on Tuesday, September 12th. Piper Jaffray Companies restated an “overweight” rating and issued a $226.00 target price (up previously from $202.00) on shares of Illumina in a research report on Monday, October 9th. Citigroup raised their target price on Illumina from $180.00 to $220.00 and gave the company a “neutral” rating in a research report on Wednesday, October 25th. Morgan Stanley raised their target price on Illumina from $122.00 to $135.00 and gave the company an “underweight” rating in a research report on Thursday, December 14th. Finally, Zacks Investment Research downgraded Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, October 31st. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have issued a buy rating to the company. Illumina has an average rating of “Buy” and an average price target of $202.60.
Illumina (NASDAQ ILMN) opened at $218.49 on Tuesday. The stock has a market capitalization of $31,899.54, a P/E ratio of 40.92, a price-to-earnings-growth ratio of 3.61 and a beta of 0.79. The company has a current ratio of 4.22, a quick ratio of 3.73 and a debt-to-equity ratio of 0.41. Illumina has a 1 year low of $127.28 and a 1 year high of $230.72.
In other Illumina news, Director Jay T. Flatley sold 20,000 shares of the firm’s stock in a transaction on Tuesday, October 10th. The stock was sold at an average price of $203.27, for a total transaction of $4,065,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert S. Epstein sold 1,250 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $226.55, for a total value of $283,187.50. Following the sale, the director now directly owns 9,088 shares of the company’s stock, valued at approximately $2,058,886.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 136,276 shares of company stock valued at $28,766,178. Insiders own 0.89% of the company’s stock.
A number of hedge funds have recently bought and sold shares of ILMN. Parametric Portfolio Associates LLC boosted its position in shares of Illumina by 41.2% during the third quarter. Parametric Portfolio Associates LLC now owns 290,458 shares of the life sciences company’s stock worth $57,859,000 after buying an additional 84,690 shares during the period. Moors & Cabot Inc. boosted its position in shares of Illumina by 7.1% during the third quarter. Moors & Cabot Inc. now owns 7,500 shares of the life sciences company’s stock worth $1,497,000 after buying an additional 500 shares during the period. IFM Investors Pty Ltd purchased a new position in shares of Illumina during the third quarter worth $804,000. DF Dent & Co. Inc. boosted its position in shares of Illumina by 4.0% during the third quarter. DF Dent & Co. Inc. now owns 486,530 shares of the life sciences company’s stock worth $96,917,000 after buying an additional 18,741 shares during the period. Finally, Neuberger Berman Group LLC boosted its position in shares of Illumina by 10.0% during the third quarter. Neuberger Berman Group LLC now owns 5,384 shares of the life sciences company’s stock worth $1,072,000 after buying an additional 491 shares during the period. 91.60% of the stock is owned by institutional investors.
About Illumina
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.